Immunophenotype of neoplastic plasma cells in AL amyloidosis

Journal of Clinical Pathology

Volumn 62, Issue 8, 2009, Pages 724-730

  Deshmukh, M ^a   Elderfield, K ^a   Rahemtulla, A ^a   Naresh, Kikkeri N ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID LIGHT CHAIN; CD20 ANTIGEN; CD56 ANTIGEN; CD79A ANTIGEN; CYCLIN D1; EPITHELIAL MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MALE; MYELOMA; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; AMYLOID; AMYLOIDOSIS; ANTIGENS, NEOPLASM; BIOPSY; BONE MARROW CELLS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; PROGNOSIS;

EID: 68149156426     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.065474     Document Type: Article

References (50)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909.
2. Bellotti V, Merlini G, Bucciarelli E, et al. Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. Br J Haematol 1990;74:65-69 (Pubitemid 20043574)
3. Glenner GG, Terry W, Harada M, et al. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science 1971;172:1150-1151
4. Hawkins PN, Wootton R, Pepys MB. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J Clin Invest 1990;86:1862-1869
5. Gillmore JD, Davies J, Iqbal A, et al. Allogeneic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol 1998;100:226-228 (Pubitemid 28051865)
6. Abraham RS, Katzmann JA, Clark RJ, et al. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003;119:274-278
7. Grogan TM, Van Camp B, Kyle RA, et al. Plasma cell neoplasms. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:143.
8. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
9. Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol 2008;141:413-422 (Pubitemid 351550561)
10. Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer 2006;42:1671-1683 (Pubitemid 44118778)
11. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757
12. Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004;121:482-488 (Pubitemid 38392955)
13. Mateo G, Castellanos M, Rasillo A, et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 2005;11:3661-3667 (Pubitemid 40685582)
14. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332-2336 (Pubitemid 38326254)
15. Robillard N, Wuilleme S, Lode L, et al. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. Leukemia 2005;19:2021-2022 (Pubitemid 41554021)
16. Naresh KN, Lampert I, Hasserjian R, et al. Optimal processing of bone marrow trephine biopsy: the Hammersmith Protocol. J Clin Pathol 2006;59:903-911 (Pubitemid 44422841)
17. Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001;28:637-642 (Pubitemid 33014596)
18. Wechalekar AD, Goodman HJ, Lachmann HJ, et al. Safety and efficacy of riskadapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007;109:457-464
19. Hasserjian RP, Goodman HJ, Lachmann HJ, et al. Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients. Histopathology 2007;50:567-573 (Pubitemid 46495828)
20. Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 1998;82:1501-1505
21. Menke DM, Greipp PR, Colon-Otero G, et al. Bone marrow aspirate immunofluorescent and bone marrow biopsy immunoperoxidase staining of plasma cells in histologically occult plasma cell proliferative marrow disorders. Arch Pathol Lab Med 1994;118:811-814 (Pubitemid 24249119)
22. Wolf BC, Kumar A, Vera JC, et al. Bone marrow morphology and immunology in systemic amyloidosis. Am J Clin Pathol 1986;86:84-88 (Pubitemid 16033663)
23. Wolf BC, Brady K, O'Murchadha MT, et al. An evaluation of immunohistologic stains for immunoglobulin light chains in bone marrow biopsies in benign and malignant plasma cell proliferations. Am J Clin Pathol 1990;94:742-746
24. Swan N, Skinner M, O'Hara CJ. Bone marrow core biopsy specimens in AL (primary) amyloidosis. A morphologic and immunohistochemical study of 100 cases. Am J Clin Pathol 2003;120:610-616 (Pubitemid 37186055)
25. Wu SS, Brady K, Anderson JJ, et al. The predictive value of bone marrow morphologic characteristics and immunostaining in primary (AL) amyloidosis. Am J Clin Pathol 1991;96:95-99
26. Joshi R, Horncastle D, Elderfield K, et al. Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients. J Clin Pathol 2008;61:213-216 (Pubitemid 351218883)
27. Perfetti V, Garini P, Vignarelli MC, et al. Diagnostic approach to and follow-up of difficult cases of AL amyloidosis. Haematologica 1995;80:409-415
28. Perfetti V, Colli Vignarelli M, Anesi E, et al. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica 1999;84:218-221 (Pubitemid 29476924)
29. Harrison CJ, Mazzullo H, Ross FM, et al. Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Haematol 2002;117:427-435 (Pubitemid 34451161)
30. Hayman SR, Bailey RJ, Jalal SM, et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood 2001;98:2266-2268
31. Garand R, Avet-Loiseau H, Accard F, et al. t(11;14) and t(4;14) Translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003;17:2032-2035
32. Tinguely M, Jenni B, Reineke T, et al. Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays. Am J Surg Pathol 2007;31:690-696 (Pubitemid 46684207)
33. Almeida J, Orfao A, Ocqueteau M, et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol 1999;107:121-131 (Pubitemid 29500817)
34. Bataille R, Jego G, Robillard N, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of ''many and multiple myelomas'' and of new targets for myeloma therapy. Haematologica 2006;91:1234-1240
35. Zojer N, Konigsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000;95:1925-1930 (Pubitemid 30151627)
36. Mason DY, Cordell JL, Brown MH, et al. CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples. Blood 1995;86:1453-1459
37. Chang H, Samiee S, Yi QL. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalanbased chemotherapy and autologous stem cell transplant. Leuk Lymphoma 2006;47:43-47 (Pubitemid 43101723)
38. Dunphy CH, Nies MK, Gabriel DA. Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma. Appl Immunohistochem Mol Morphol 2007;15:248-254
39. Hundemer M, Klein U, Hose D, et al. Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplant 2007;40:1033-1037 (Pubitemid 350142555)
40. Martin P, Santon A, Bellas C. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis. Histopathology 2004;44:375-380 (Pubitemid 38491305)
41. Pruneri G, Fabris S, Baldini L, et al. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol 2000;156:1505-1513 (Pubitemid 30646690)
42. Rasmussen T, Knudsen LM, Johnsen HE. Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma. Eur J Haematol 2001;67:296-301. (Pubitemid 34135442)
43. Soverini S, Cavo M, Cellini C, et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with highdose chemotherapy and single or double autologous transplantation. Blood 2003;102:1588-1594 (Pubitemid 37022546)
44. Troussard X, Avet-Loiseau H, Macro M, et al. Cyclin D1 expression in patients with multiple myeloma. Hematol J 2000;1:181-185
45. Vasef MA, Medeiros LJ, Yospur LS, et al. Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod Pathol 1997;10:927-932
46. Baldus SE, Palmen C, Thiele J. MUC1 (EMA) expressing plasma cells in bone marrow infiltrated by plasma cell myeloma. Histol Histopathol 2007;22:889-893 (Pubitemid 47034155)
47. Brossart P, Schneider A, Dill P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 2001;61:6846-6850 (Pubitemid 32896509)
48. Cloosen S, Gratama J, van Leeuwen EB, et al. Cancer specific mucin-1 glycoforms are expressed on multiple myeloma. Br J Haematol 2006;135:513-516 (Pubitemid 44583416)
49. Pileri S, Poggi S, Baglioni P, et al. Histology and immunohistology of bone marrow biopsy in multiple myeloma. Eur J Haematol Suppl 1989;51:52-59 (Pubitemid 20118751)
50. Kyle RA. Monoclonal proteins and renal disease. Annu Rev Med 1994;45:71-77